A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 Year(s) - 79 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1) Subject has no history of prior systemic anti-lymphoma therapy for DLBCL (including any definitive radiotherapy with curative intent) other than corticosteroids with or without vincristine during prephase treatment, or non-curative intent palliative radiotherapy with the stipulation that radiated lesions cannot be selected as target lesion for response assessment
    2. 2) Subject is planned to receive treatment with 6 cycles of standard R-CHOP
    3. 3) Subject must have newly diagnosed, histologically confirmed CD20+ DLBCL

You may not be eligible for this study if the following are true:

    1. 1) Has history of primary mediastinal lymphoma, or mediastinal or pericardial radiation
    2. 2) Has a primary CNS tumor or known CNS involvement at Screening
    3. 3) Has clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.